Inventor profile of:

Scott E. STROME

City:

Rochester, Minnesota

Country:

United States

Published Applications:

21

Last publication date:

2024-10-24

Top Assignees for applications by Scott E. STROME

The entities that hold a legal rights for patent applications filed by inventor STROME Scott E.:

Recent patent applications by STROME Scott E.

Scott E. STROME from Rochester, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-10-24
US20240352120A1
Chemistry; metallurgy

COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET

#2 | 2021-12-09
US20210380690A1
Chemistry; metallurgy

Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target

#3 | 2020-01-02
US20200002419A1
Chemistry; metallurgy

Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target

#4 | 2018-06-28
US20180179281A1
Chemistry; metallurgy

COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET

#5 | 2018-04-12
US20180100015A1
Chemistry; metallurgy

COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET

#6 | 2016-09-15
US20160264667A1
Chemistry; metallurgy

COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET

#7 | 2016-09-08
US20160257953A1
Chemistry; metallurgy

COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET

#8 | 2016-08-25
US20160245816A1
Physics

Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target

#9 | 2015-02-12
US20150044165A1
Human necessities

COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET

#10 | 2012-03-08
US20120058047A9
Human necessities

METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION

#11 | 2012-02-02
US20120027759A1
Chemistry; metallurgy

METHODS OF ENHANCING T CELL RESPONSIVENESS

#12 | 2011-08-18
US20110200620A1
Chemistry; metallurgy

B7-H1 and methods of diagnosis, prognosis, and treatment of cancer

#13 | 2011-05-05
US20110104049A1
Human necessities

METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION

#14 | 2010-10-21
US20100266611A1
Human necessities

Enhancement of immune responses by 4-1BB-binding agents

#15 | 2010-09-14
US10127282
-

Methods of enhancing T cell responsiveness

#16 | 2008-11-11
US10719477
-

Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells

#17 | 2008-01-24
US20080019905A9
Human necessities

Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection

#18 | 2006-08-24
US20060188439A1
Human necessities

Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection

#19 | 2006-08-17
US20060182744A1
Chemistry; metallurgy

Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof

#20 | 2006-04-20
US20060083744A1
Chemistry; metallurgy

B7-H1 and methods of diagnosis, prognosis, and treatment of cancer

#21 | 2005-01-20
US20050013811A1
Human necessities

Enhancement of immune responses by 4-1bb-binding agents

InventorID:

1065385 ⎘